Rejuran Healer vs Exosome Boosters: Which Fits Your Skin?

For hydration and texture concerns, polynucleotide (PN) injectables such as Rejuran Healer are usually the first option considered in Korea, because they hold medical device approval for injection into skin, while most exosome products are registered as topical cosmetics with a thinner, injection-specific evidence base. The two categories differ across four practical points: how they are legally allowed to be used, the type of clinical evidence behind them, how many sessions they call for, and the recovery they leave behind. A diagnosis, not the product name, should decide which one fits a given concern.

Hello, I’m Dr. Kim Yeonjin, director of UH CELL Clinic’s Gangnam branch. In consultation I hear a version of the same question often: “Which gives better glass skin, Rejuran Healer or an exosome skin booster?” The short answer is that for hydration alone, PN sits ahead. The reason lies in how each category is allowed to be used here and how much evidence has actually been collected on it, not in one ingredient outworking the other.

What Patients Usually Mean by “Glass Skin”

When a patient says their skin needs more glow, the concern is usually one of three separate problems. The surface may be dry enough that makeup sits unevenly and flaking shows by afternoon. The texture may be rough enough that light scatters instead of reflecting evenly. Or fine lines may sit over shallow volume loss, casting small shadows. These are different layers of the same complaint, so treatments that get grouped under one marketing label do not fit all three equally.

Clinical studies measure this with skin hydration, transepidermal water loss, elasticity, pore volume, and surface roughness. In consultation, I check the same markers before recommending anything. The visible glow matters less at that stage than which of these readings is actually off, and by how much.

What Polynucleotide Injectables Do

Rejuran Healer is built on polynucleotides extracted from salmon DNA, and in Korea it is approved as a medical device for injection into skin. Medipana News reported in 2023 that the packaging and instructions for use for these products specify slow injection into the skin, meaning the needle-based delivery sits inside the approved use, not outside it.

On mechanism, an international panel of experts, in a review published in Clinical, Cosmetic and Investigational Dermatology, describes PN as forming a water-retaining mesh at the injection site that supports tissue reorganization and hydration. The same review reports that a randomized, double-blind, split-face trial in 27 subjects, comparing PN against hyaluronic acid at the periorbital and under-eye area, found greater improvement in elasticity and skin tone on the PN side.

A separate line of evidence looked directly at hydration. A research team led by Teramo, publishing in the Journal of Cosmetic Dermatology (2026), followed 28 subjects treated with a different PN-based injectable (not Rejuran specifically) across the face, neck, and décolleté, given in three sessions two weeks apart, with follow-up at two and four months. The study reported a significant improvement on an overall aesthetic improvement scale. Because the product differs from Rejuran Healer, this reads as evidence for the PN category rather than a direct result for this specific brand.

Periorbital comparisons go a step further. A literature review published in the Journal of Cutaneous and Aesthetic Surgery found that around the eyes, PN products outperformed uncrosslinked hyaluronic acid filler on elasticity and hydration, and also showed a larger improvement in pore volume and skin roughness, with no adverse events recorded across the reviewed studies. We have written separately about how Rejuran compares to a standard skin booster injection on ingredient grounds, which is worth reading if you are deciding between those two rather than between PN and exosomes.

Where the Evidence on Exosomes Actually Sits

Exosomes are small vesicles released by cells that carry regenerative signaling molecules, and research interest in them is real. The shape of the evidence, though, is different from PN’s.

Navnit Kaur Dhaliwal and colleagues published a systematic review in the Journal of Cosmetic Dermatology (2026) that screened 256 references and included eight studies combining microneedling with topical exosome application. Split-face trials in that review reported better improvement in wrinkle roughness, elasticity, hydration, and pigmentation than microneedling alone, with biopsy work in some studies confirming increased collagen density. The same authors were explicit about the limits: sample sizes were small, follow-up did not extend past six months in any included study, exosome source varied widely (adipose tissue, umbilical cord-derived stem cells, plant-derived, and probiotic-derived material among them), and the regulatory status of the products used was not always disclosed.

Almost all of the improvement in that review came from a specific pairing: microneedling to open microchannels, followed by topical exosome application. That is a different procedure from an exosome product delivered by injection. A scoping review in the Journal of Drugs in Dermatology covering studies published between 2020 and 2025 found that 76 percent of 17 human studies reported improvement in wrinkles, pigmentation, elasticity, hydration, or scarring, but also recorded adverse events including post-injection granuloma, tissue necrosis, and allergic reaction, concentrated in the injected cases rather than the topical ones.

Why Regulatory Status Decides the Delivery Method

Korean regulation draws a clear line here. Medipana News reported in 2023 that the Ministry of Food and Drug Safety stated injection through a syringe or microneedle into skin is permitted only for products classified as drugs or medical devices. The same report noted that a number of exosome products on the market are registered as topical cosmetics, with usage instructions that describe mixing and applying the product to the skin surface for absorption, not injecting it.

That distinction has produced enforcement action, not just guidance. Pharm News reported in 2025 that the Ministry of Health and Welfare suspended a physician’s license for three months after a cosmetic-registered exosome product was administered by hand injection to a patient’s face. The court held that a product’s classification as a cosmetic does not change how it is evaluated once it is used by injection rather than topical application, and upheld the suspension on that basis. Daily Pharm had earlier reported that a 2022 National Assembly audit flagged exosome ingredients registered as cosmetics rather than drugs as a regulatory gap.

So “exosome skin booster” actually covers two distinct products in practice: a topical application used after microneedling, and a cosmetic-registered product used off-label by injection. Most patients asking about exosomes mean the first one. Without a specific conversation about which product and which delivery method, it is possible to book the second by accident.

Comparing the Two Directly

	PN injectables (Rejuran Healer)	Exosome boosters
Korean regulatory status	Approved as a medical device for injection (Medipana News, 2023)	Most products registered as topical cosmetics; injection use falls outside approval (Medipana News 2023; Pharm News 2025)
How the evidence was built	Intradermal injection trials, including a randomized double-blind split-face comparison	Mostly microneedling-plus-topical combinations; small samples, follow-up under six months (Dhaliwal et al., 2026)
What it targets	Hydration, skin barrier, texture, elasticity	Wrinkle texture, pigmentation, elasticity, hydration; results vary widely by product
Reported adverse events	None recorded in the periorbital comparison review	Delayed granuloma, hyperpigmentation, tissue necrosis, and allergic reaction reported, mostly with injected use
Session guidance	Three sessions four weeks apart is the protocol proposed in the expert panel review	No standardized protocol established

For a hydration-first goal, this table is why PN comes first: the targeted markers line up with hydration and texture, the injection route is inside the approved use, and there is a published session interval to plan around.

Sessions, Recovery, and Your Travel Window

The expert panel review proposes injecting 0.02 to 0.04 mL per point at 3 to 5 mm spacing, totaling 2 to 4 mL per session, across three sessions spaced four weeks apart. This treatment plan spans three sessions rather than a single visit. If your trip only allows one session, tell me that during consultation so we can set expectations against what three sessions would achieve, rather than comparing your one-session outcome to a full course.

Recovery involves visible injection points and some swelling, since the treatment uses a fine needle placed repeatedly into the dermis. I recommend avoiding strenuous exercise, sauna use, and alcohol for about a week afterward, along with consistent sun protection. How long redness or swelling lasts varies by individual.

How We Decide This in Consultation at Our Gangnam Branch

I do not start from a product name. I start by checking skin thickness, elasticity, and hydration to see which marker is actually off, then choose the category from there. If hydration and texture are the primary complaint, PN is the starting point. If volume loss or deeper dermal structure is the leading issue, a different injectable approved specifically for that use gets evaluated instead. When both are present, I sequence them with spacing rather than combining everything into one visit.

Our Gangnam branch is inside UH FLAT SIGNATURE Gangnam, so the recovery step after a session is a short walk back to your room rather than a separate trip. Guests staying at an UHC hotel can choose one complimentary recovery option, either a 30-minute oxygen chamber session or a vitamin IV drip; choosing both adds a charge of 55,000 KRW for the IV drip (full conditions are listed on our promotion page). Japanese, Chinese, and English interpreting staff are on site for consultations.

What to Confirm Before You Book

• Ask whether the specific product you are being offered is approved for injection as a device or drug, or registered as a topical cosmetic, by name rather than category label.
• If exosomes are recommended, ask whether the plan is topical application after microneedling or an injection, and what device is paired with it if topical.
• Confirm the total number of sessions planned, the interval between them, and how many of those you will actually receive during this visit.
• Work backward from your flight date to the length of time injection marks typically take to fade before deciding on timing.
• Mention any history of fish or seafood allergy before treatment is planned.

FAQ

Is Rejuran Healer the same as Rejuran HB+?

No. Rejuran Healer is built around polynucleotides alone, focused on repairing damaged skin and refining texture. Rejuran HB+ adds hyaluronic acid to that base, aimed at hydration together with shallow volume support. Which one fits depends on whether fine-line hollowing is present, and that is assessed during consultation rather than decided in advance.

Can I get a PN injectable if I have a fish allergy?

The literature review in the Journal of Cutaneous and Aesthetic Surgery recommends a patch test for patients with a history of fish or seafood sensitivity before proceeding. If you have that history, mention it during consultation; depending on the result, a different injectable category may be a better fit.

What about getting exosomes applied topically instead of injected?

That is where the published evidence is actually concentrated. The studies included in the Dhaliwal et al. 2026 systematic review paired microneedling with topical exosome application, though the authors note small sample sizes, follow-up under six months, and meaningful variation between products, so results should not be treated as settled.

How soon will I see a difference?

The protocol proposed in the PN expert panel review is three sessions four weeks apart, so this is a treatment to evaluate across a course rather than after a single visit. The Teramo team’s 2026 study tracked improvement out to two and four months following three injections. Individual skin condition affects the timeline.

※ Skin response and recovery time vary by individual. Please consult a licensed physician for an accurate diagnosis and treatment plan.